RxDoctor Payments Data

Daniel Lamphier, MD

Family Medicine · Queenstown, MDNPI 1710206321

Payments from drug & device makers

$6,379in general payments, 2019–2025

Across 377 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$446
  • GSK$428
  • Lilly USA, LLC$412
  • Pfizer$381
  • AstraZeneca$371
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,372100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,379 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$239,067
Medicare patients
677
Services billed
7,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$114,066
JardianceEmpagliflozin58$79,139
EliquisApixaban67$77,295
TrulicityDulaglutide29$56,468
XifaxanRifaximin15$49,892
XareltoRivaroxaban19$32,286
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$25,117
JanuviaSitagliptin Phosphate18$23,758
Tresiba Flextouch U-200Insulin Degludec19$22,049
Breo ElliptaFluticasone/Vilanterol19$15,763
MounjaroTirzepatide14$14,134
Mesalamine13$10,741
Atorvastatin Calcium472$5,978
Rosuvastatin Calcium157$3,824
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,532$114,06661 claims
Boehringer IngelheimJardiance$192$79,13958 claims
PfizerEliquis$381$77,29567 claims
Lilly USA, LLCTrulicity, Mounjaro$412$70,60143 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$54$49,89215 claims
GSKTrelegy Ellipta, Breo Ellipta$428$40,88036 claims
Johnson & JohnsonXarelto$33$32,28619 claims
MerckJanuvia$265$23,75818 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$39$2,614277 claims
AbbVieSynthroid$334$2,02037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Queenstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →